Stivarga (regorafenib) — CareFirst (Caremark)

Initial criteria

• Requested for subsequent treatment of relapsed (with or without radiation), progressive, or metastatic Ewing sarcoma as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months